Aldeyra Therapeutics (NASDAQ:ALDX) Stock Rating Reaffirmed by HC Wainwright

Aldeyra Therapeutics (NASDAQ:ALDXGet Rating)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued to investors on Wednesday, Zacks.com reports.

Separately, StockNews.com initiated coverage on Aldeyra Therapeutics in a research report on Thursday, March 31st. They set a “sell” rating for the company. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $18.00.

Shares of NASDAQ ALDX opened at $3.65 on Wednesday. The stock has a 50 day moving average price of $4.27 and a 200 day moving average price of $5.44. Aldeyra Therapeutics has a 52 week low of $3.00 and a 52 week high of $13.48. The company has a debt-to-equity ratio of 0.08, a quick ratio of 19.77 and a current ratio of 19.77. The stock has a market capitalization of $212.06 million, a PE ratio of -3.41 and a beta of 1.51.

Aldeyra Therapeutics (NASDAQ:ALDXGet Rating) last issued its quarterly earnings results on Thursday, March 17th. The biotechnology company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.04. During the same period last year, the firm earned ($0.35) EPS. As a group, research analysts forecast that Aldeyra Therapeutics will post -1.32 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the business. Eagle Asset Management Inc. raised its stake in Aldeyra Therapeutics by 3.5% in the fourth quarter. Eagle Asset Management Inc. now owns 1,392,936 shares of the biotechnology company’s stock valued at $5,655,000 after buying an additional 46,468 shares during the period. Assenagon Asset Management S.A. raised its stake in Aldeyra Therapeutics by 3,594.8% in the first quarter. Assenagon Asset Management S.A. now owns 975,139 shares of the biotechnology company’s stock valued at $4,334,000 after buying an additional 948,747 shares during the period. Geode Capital Management LLC raised its stake in Aldeyra Therapeutics by 0.4% in the third quarter. Geode Capital Management LLC now owns 901,917 shares of the biotechnology company’s stock valued at $7,918,000 after buying an additional 3,400 shares during the period. Knoll Capital Management LLC raised its stake in Aldeyra Therapeutics by 33.4% in the fourth quarter. Knoll Capital Management LLC now owns 759,405 shares of the biotechnology company’s stock valued at $3,038,000 after buying an additional 190,000 shares during the period. Finally, Prosight Management LP raised its stake in Aldeyra Therapeutics by 23.5% in the third quarter. Prosight Management LP now owns 735,000 shares of the biotechnology company’s stock valued at $6,453,000 after buying an additional 139,761 shares during the period. Hedge funds and other institutional investors own 68.00% of the company’s stock.

Aldeyra Therapeutics Company Profile (Get Rating)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

Featured Stories

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.